Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 15;17(5):104076.
doi: 10.4251/wjgo.v17.i5.104076.

Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target

Jun-Nan Liao  1 , Wen-Juan Ni  2 , Ping-Hui Wu  1 , Ya-Dong Yang  1 , Ying Yang  2 , Wen Long  2 , Mei-Zhen Xie  2 , Xiu-Zhi Zhu  2 , Fu-Hua Xie  2 , Xiao-Min Leng  3
Affiliations
Review

Switching from messenger RNAs to noncoding RNAs, METTL3 is a novel colorectal cancer diagnosis and treatment target

Jun-Nan Liao et al. World J Gastrointest Oncol. .

Abstract

N6-methyladenosine (m6A) modification, one of the most prevalent RNA epigenetic modifications in eukaryotes, constitutes over 60% of all RNA methylation modifications. This dynamic modification regulates RNA processing, maturation, nucleocytoplasmic transport, translation efficiency, phase separation, and stability, thereby linking its dysregulation to diverse physiological and pathological processes. METTL3, a core catalytic component of the methyltransferase complex responsible for m6A deposition, is frequently dysregulated in diseases, including colorectal cancer (CRC). Although METTL3's involvement in CRC pathogenesis has been documented, its precise molecular mechanisms and functional roles remain incompletely understood. METTL3 mediates CRC progression-encompassing proliferation, invasion, drug resistance, and metabolic reprogramming-through m6A-dependent modulation of both coding RNAs and noncoding RNAs. Its regulatory effects are primarily attributed to interactions with key signaling pathways at multiple stages of CRC development. Emerging evidence highlights METTL3 as a promising biomarker for CRC diagnosis and prognosis, as well as a potential therapeutic target. By synthesizing recent advances in METTL3 research within CRC, this review provides critical insights into novel strategies for clinical diagnosis and targeted therapy.

Keywords: Biomarker; Colorectal cancer; Epigenetics; METTL3; N6-methyladenosine; Targeted treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Dynamic regulation of N6-methyladenosine modification. N6-methyladenosine (m6A) writers, erasers, and readers control the process of m6A modification. Writers (METTL3, METTL14, WTAP, METTL5, and METTL16) catalyze m6A deposition, erasers (FTO and ALKBH5) remove methyl groups, and readers (YTHDF1/YTHDF2/YTHDF3, YTHDC1/YTHDC2/YTHDC3, IGF2BP1/IGF2BP2/IGF2BP3) decode these marks to influence RNA stability, messenger RNA translation, RNA degradation, translocation, RNA splicing, structure switching, and primary microRNA processing. M6A: N6-methyladenosine.
Figure 2
Figure 2
METTL3-mediated N6-methyladenosine modification of messenger RNAs in colorectal cancer. METTL3 participates in colorectal cancer (CRC) by regulating N6-methyladenosine modification of messenger RNAs (mRNAs) involved in proliferation, invasion and metastasis, metabolic disorder, and resistance of CRC cells. Every mRNA was detailed with a name. HK2: Hexokinase 2; GLUT1: Glucose transporter type 1; mRNAs: Messenger RNAs; m6A: N6-methyladenosine; CRC: Colorectal cancer.
Figure 3
Figure 3
METTL3-mediated N6-methyladenosine modification of noncoding RNAs in colorectal cancer. METTL3 participates in colorectal cancer (CRC) by regulating N6-methyladenosine modification of noncoding RNAs (ncRNAs) involved in proliferation, invasion and metastasis, metabolic disorder, and resistance of CRC cells. Each ncRNA was detailed with a name. ncRNAs: Noncoding RNAs; m6A: N6-methyladenosine; CRC: Colorectal cancer.
Figure 4
Figure 4
Expression and function analysis of METTL3. A: Pan-cancer analysis of METTL3; B: Expression of METTL3 in colon adenocarcinoma (COAD); C: METTL3 expression across COAD stages; D: Prognosis of METTL3 in COAD; E: Integration of the top 150 METTL3 target genes; F: Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of METTL3 targets; G: Drug-protein interaction analysis of Patupilone, YM-155, KIN001-266, and METTL3 in prostate adenocarcinoma. TCGA: The Cancer Genome Atlas; TPM: Transcripts per million; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma multiforme; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PAAD: Pancreatic adenocarcinoma; PRAD: Prostate adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; READ: Rectum adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; UCEC: Uterine corpus endometrial carcinoma; KEGG: Kyoto Encyclopedia of Genes and Genomes.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Imamura F, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, Mozaffarian D Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDE) Dietary quality among men and women in 187 countries in 1990 and 2010: a systematic assessment. Lancet Glob Health. 2015;3:e132–e142. - PMC - PubMed
    1. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender and alcohol consumption: patterns from the multinational GENACIS project. Addiction. 2009;104:1487–1500. - PMC - PubMed
    1. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998;339:1277–1284. - PubMed
    1. Kowalczyk M, Orłowski M, Siermontowski P, Mucha D, Zinkiewicz K, Kurpiewski W, Zieliński E, Kowalczyk I, Pedrycz A. Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients. BMC Cancer. 2018;18:213. - PMC - PubMed

LinkOut - more resources